Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23423652 | 0.80 | KCNN4 (0.44) | TAAR1KCNN4MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL12566248 | 0.77 | KDM4E (0.47) | TAAR1KCNN4MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL13061198 | 0.77 | SMN1; SMN2 (0.48) | TAAR1KCNN4SMN1; SMN2CYP2C19ALDH1A1 | |
| SCHEMBL23374742 | 0.75 | CYP2D6 (0.46) | TAAR1KCNN4MAPK1KMT2ACYP2C19 | |
| SCHEMBL1149712 | 0.74 | KCNN4 (0.59) | TAAR1KCNN4MAPK1MAPTKMT2A | |
| SCHEMBL7347654 | 0.74 | MAOB (0.47) | KCNN4MAPK1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8084282 | 0.74 | TAAR1 (0.55) | TAAR1 | |
| SCHEMBL12478391 | 0.72 | SIGMAR1 (0.41) | TAAR1KCNN4KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7355367 | 0.72 | LMNA (0.49) | KCNN4MAPK1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL12610396 | 0.72 | CHRM2 (0.38) | TAAR1KCNN4KMT2ASMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2020-11-24 | — | — | US | disclosed |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | TAAR1 3561/4885KCNN4 3831/4885MAPK1 4087/4885 |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | TAAR1 3561/4885KCNN4 3831/4885MAPK1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.